Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jul;173(3):751-757.
doi: 10.1007/s11060-025-05020-1. Epub 2025 May 28.

Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104

Vihang Nakhate  1 , Ina Ly  1 , Alona Muzikansky  1 , Otto Rapalino  2 , Jeffrey C Allen  3 , Jaishri O Blakeley  4 , Jian L Campian  5 , D Wade Clapp  6 , Girish Dhall  7 , Rakesh K Jain  8 , Matthias A Karajannis  9 , Roger J Packer  10 , James Tonsgard  11 , Nicole J Ullrich  12 , Bruce R Korf  7 , Michael J Fisher  13 , Scott R Plotkin  14   15 ; Neurofibromatosis Clinical Trials Consortium
Affiliations
Clinical Trial

Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104

Vihang Nakhate et al. J Neurooncol. 2025 Jul.

Abstract

Purpose: Bevacizumab treatment is associated with imaging and hearing responses in progressive vestibular schwannoma (VS) caused by NF2-related schwannomatosis (NF2-SWN). However, its effect on co-existing intracranial non-vestibular schwannomas (NVS) and meningiomas is unclear.

Methods: We retrospectively analyzed tumor volumes of non-target intracranial NVS and meningiomas in patients with NF2-SWN and progressive VS who were prospectively treated with bevacizumab for two years on the Neurofibromatosis Clinical Trials Consortium (NFCTC) trial NF104 (NCT01767792). Radiographic response (RR) or progression (PD) were defined as ≥ 20% decrease or ≥ 20% increase in tumor volume compared to baseline, respectively. All other responses were defined as stable disease.

Results: A total of 40 meningiomas in eight patients and 12 NVS in six patients were evaluated across 22 enrolled trial participants. On best response analysis, RR occurred in 13% (5/40) of meningiomas and in 42% (5/12) of NVS. On a per-patient basis, RR for meningioma occurred in 38% (3/8) of patients and for NVS in 67% (4/6) of patients. RR in two NVS were durable throughout the study period. During two years of treatment, PD occurred in 55% (22/40) of meningiomas and in 8% (1/12) of NVS. Median time to tumor progression was 15 months for meningiomas and was not reached for NVS.

Conclusions: We observed greater activity of bevacizumab against intracranial NVS compared to meningioma, evidenced by more favorable RR rates, durability of response, and rates of PD. Potential biological differences between meningiomas and schwannomas that underlie this differential response to bevacizumab warrant further investigation.

Keywords: Bevacizumab; Meningioma; NF2; Non-vestibular schwannoma; Schwannomatosis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: VN, IL, AM, OR, JCA, JOB, JLC, DWC, GD, RKJ, MAK, RJP, JT, NJU, BRK, and MJF declare no relevant competing interests. SRP is co-founder of NFlection Therapeutics and NF2 Therapeutics, and a consultant for Akouos and SonALAsense.

References

    1. Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO et al (2022) Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med 24(9):1967–1977 - DOI - PubMed
    1. Wang JZ, Landry AP, Raleigh DR, Sahm F, Walsh KM, Goldbrunner R et al (2024) Meningioma: international consortium on meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neurooncology 26(10):1742–1780
    1. Aboukais R, Zairi F, Bonne NX, Baroncini M, Schapira S, Vincent C et al (2015) Causes of mortality in neurofibromatosis type 2. Br J Neurosurg 29(1):37–40 - DOI - PubMed
    1. Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A et al (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358–367 - DOI - PubMed - PMC
    1. Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T et al (2019) Multicenter, prospective, phase II and biomarker study of High-Dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular Schwannoma. J Clin Oncol 37(35):3446–3454 - DOI - PubMed - PMC

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources